Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Evotec SE before investing.

In this article, we go over a few key elements for understanding Evotec SE’s stock price such as:

• Evotec SE’s current stock price and volume
• Why Evotec SE’s stock price changed recently
• Upgrades and downgrades for EVO from analysts
• EVO’s stock price momentum as measured by its relative strength

About Evotec SE (EVO)

Before we jump into Evotec SE’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases. It is also developingcentral nervous system (CNS) and cardiometabolic diseases; and animal and women health. The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore. In addition, it has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB. Further, the company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital. Evotec SE has strategic collaboration with Almirall, S.A. for the development of novel therapeutics for severe skin diseases, including a range of immune-mediated inflammatory conditions. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Want to learn more about Evotec SE’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Evotec SE.

Evotec SE’s Stock Price as of Market Close

As of July 29, 2026, 12:30 PM, CST, Evotec SE’s stock price was $1.925.

Evotec SE is down 1.79% from its previous closing price of $1.960.

During the last market session, Evotec SE’s stock traded between $1.920 and $1.970. Currently, there are approximately 204.73 million shares outstanding for Evotec SE.

Evotec SE’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Evotec SE Stock Price History

Evotec SE’s (EVO) price is currently down 31.25% so far this month.

During the month of July, Evotec SE’s stock price has reached a high of $2.930 and a low of $1.910.

Over the last year, Evotec SE has hit prices as high as $4.320 and as low as $1.910. Year to date, Evotec SE’s stock is down 37.5%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Evotec SE Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 28, 2026, there were analysts who downgraded Evotec SE’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Evotec SE’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Evotec SE’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Evotec SE’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Evotec SE (EVO) by visiting AAII Stock Evaluator.

Relative Price Strength of Evotec SE

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 28, 2026, Evotec SE has a weighted four-quarter relative price strength of -23.30%, which translates to a Momentum Score of 10 and is considered to be Very Weak.

Want to learn more about how Evotec SE is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Evotec SE Stock Price: Bottom Line

As of July 29, 2026, Evotec SE’s stock price is $1.925, which is down 1.79% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Evotec SE stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.